Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 2,708 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Autologous hematopoietic stem cell transplantation Clear all

Conditions: Multiple Myeloma
Interventions: Iberdomide, Daratumumab/rHuPH20 Co-formulation; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Detroit, Michigan • Lansing, Michigan

Conditions: Prostate Cancer
Interventions: Autologous dendritic cells transfected with amplified tumor RNA; Biological
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions: Depletion of CD3/CD19 in an autologous stem cell transplant; Biological
Lead sponsor: Stephan Grupp MD PhD; Other
Eligibility: 8 Years to 25 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Autism
Interventions: Autologous Cord Blood Stem Cells, Placebo; Biological
Lead sponsor: Sutter Health; Other
Eligibility: 2 Years to 7 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diffuse Large B Cell Lymphoma
Interventions: Revlimid; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Hackensack, New Jersey • Durham, North Carolina

Conditions: Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma, Melanoma
Interventions: second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab; Biological · Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 0 Years to 26 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: filgrastim, carboplatin, etoposide, isotretinoin, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 52
States / cities: Little Rock, Arkansas • Oakland, California • Sacramento, California + 45 more

Conditions: Lymphoma
Interventions: Amifostine, DHAP; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Alveolar Ridge Preservation, Tooth Extraction
Interventions: Leukocyte platelet rich fibrin plug + d-PTFE membrane, d-PTFE membrane; Biological · Device
Lead sponsor: Firas Al Yafi; Other
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Diabetic Kidney Disease, Chronic Kidney Diseases
Interventions: Renal Autologous Cell Therapy (REACT); Biological
Lead sponsor: Prokidney; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Meridian, Idaho

Conditions: Epstein-Barr Virus-Related Hodgkin Lymphoma, Epstein-Barr Virus-Related Non-Hodgkin Lymphoma, EBV Positive Plasma Cell Neoplasm
Interventions: Injection of EBV Specific CTLs; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2014
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma, High Grade B Cell Lymphoma, FL, HGBL, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B Cell Lymphoma, PMBCL, HGBL With MYC and BCL2 and/or BCL6 Rearrangements
Interventions: Prizloncabtagene Autoleucel; Biological
Lead sponsor: AbelZeta Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Gilbert, Arizona • La Jolla, California

Conditions: Glioblastoma
Interventions: B-cell vaccination; Biological
Lead sponsor: Catalina Lee Chang; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV
Interventions: KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen; Biological · Drug
Lead sponsor: Kyverna Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Palo Alto, California • Denver, Colorado • Worcester, Massachusetts + 3 more

Conditions: Allogeneic Hematopoietic Stem Cell
Interventions: fecal microbiota transplantation (FMT), No fecal microbiota transplantation (FMT), routine management; Biological · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Burns, Wound of Skin, Skin Wound
Interventions: Amnion Membrane Powder, SOC Wound Covering; Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Severe Combined Immunodeficiency
Interventions: ADA PBSC, ADA Umbilical Cord Blood Cells, Transduced Lymphocytes; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: bb1111; Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: 2 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more

Conditions: Degenerative Spondylolisthesis
Interventions: ART352-L; Biological
Lead sponsor: Ankasa Regenerative Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Rochester, Minnesota • Columbus, Ohio

Conditions: Multiple Myeloma
Interventions: Cisplatin, Cyclophosphamide, Adriamycin, Etoposide, Melphalan, Thalidomide, Dexamethasone; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Scar Formation, Autologous Fat Grafting
Interventions: Autologous Fat Grafting, No intervention; Procedure · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: plerixafor, filgrastim; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Melanoma (Skin)
Interventions: BCG vaccine, autologous tumor cell vaccine, recombinant interferon alfa, chemotherapy, cyclophosphamide; Biological · Drug
Lead sponsor: AVAX Technologies; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 17
States / cities: Rancho Mirage, California • New Haven, Connecticut • North Miami Beach, Florida + 13 more

Conditions: Severe Combined Immunodeficiency Syndrome
Interventions: CD34+ cells transduced with ADA retrovir; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 1 Month and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

Autologous Cord Blood Stem Cells for Autism

Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas

Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation

A 14 Weeks Longitudinal Study to Investigate the Effect of Leukocyte- Platelet Rich Fibrin Plug on the Quality of the Newly Formed Bone in Ridge Preservation Procedure Following a Tooth Extraction. It is a Clinical, Radiographic and Histomorphometric Study.

A Long-Term Follow-Up Study of Participants Exposed to REACT

Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL

Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy

A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Amnion Wound Covering for Enhanced Wound Healing

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

3-D Imaging Assessment of Scar Formation and Would Healing in Fat Grafted vs Non-Fat Grafted Facial Reconstruction Wound Sites

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency